– USA, MI – Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced the appointment of the industry leader and renowned authority on kidney disease, Dr. Allen R. Nissenson, M.D., F.A.C.P., to its Board of Directors, effective June 11, 2020.
“We are pleased to welcome Allen to the Board of Directors,” said Board Chairman, John McLaughlin. “We expect Allen’s clinical, regulatory and public policy expertise, combined with his senior executive experience at a large dialysis organization, will make him a valuable advisor as we seek to expand the reach and impact of Triferic in End-Stage Renal Disease.”
About Dr. Allen Nissenson
Dr. Nissenson serves as an Emeritus Professor of Medicine at the David Geffen School of Medicine at University California Los Angeles, Emeritus Chief Medical Officer of DaVita Kidney Care, and a member of the Board of Directors of Angion Biomedica Corp.
In addition to his current roles, Dr. Nissenson is the immediate past Chair of Kidney Care Partners, immediate past Co-Chair of the Kidney Care Quality Alliance, and he served as Director of the Dialysis Program and Associate Dean at the David Geffen School of Medicine. He is a former President of the Renal Physicians Association and current member of the Government Affairs Committee. Dr. Nissenson also previously served as President of the Southern California End-Stage Renal Disease Network, as well as Chair of the Medical Review Board. He earned his M.D. from Northwestern University Medical School.
“I am delighted to join Rockwell Medical’s Board of Directors at this exciting time for the Company,” said Dr. Nissenson. “I look forward to working with the Board and Executive Team to help transform the treatment of kidney patients and create value for patients and shareholders.”
About Rockwell Medical
Rockwell Medical is a biopharmaceutical company dedicated to transforming anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company’s initial focus is the treatment of anemia in end-stage renal disease. Rockwell Medical’s exclusive renal drug therapies, Triferic Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.
For more information: https://www.rockwellmed.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
